Menora Mivtachim Holdings’s Protalix BioTherapeutics PLX Stock Holding History

Menora Mivtachim Holdings’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-515	Closed	-$4K	–	72
2016 Q1	$4K	Hold	515	–	–	﹤0.01%	73
2015 Q4	$5K	Sell	515 -119,553	-100%	-$1.22M	﹤0.01%	69
2015 Q3	$1.42M	Hold	120,068	–	–	0.11%	54
2015 Q2	$2.34M	Hold	120,068	–	–	0.18%	50
2015 Q1	$2.14M	Hold	120,068	–	–	0.17%	50
2014 Q4	$2.21M	Hold	120,068	–	–	0.19%	43
2014 Q3	$2.91M	Buy	120,068 +36,460	+44%	+$1.05M	0.2%	44
2014 Q2	$3.05M	Hold	83,608	–	–	0.24%	42
2014 Q1	$3.83M	Sell	83,608 -20,500	-20%	-$957K	0.31%	43
2013 Q4	$4.05M	Hold	104,108	–	–	0.36%	45
2013 Q3	$4.72M	Sell	104,108 -5,000	-5%	-$257K	0.43%	45
2013 Q2	$5.36M	Buy	+109,108	New	+$5.79M	0.45%	47

Other funds holding PLX

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SIM

Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

Menora Mivtachim Holdings's PLX Position: Q2 2016 in Review

Menora Mivtachim Holdings sold out of Protalix BioTherapeutics (PLX) in Q2 2016, closing a stake of 515 shares — an estimated $4K sold.

Menora Mivtachim Holdings first reported a position in PLX in Q2 2013 and held it in 12 quarters. The position peaked at $5.36M in Q2 2013. 28 funds tracked by Wall St. Rank hold PLX as of Q2 2016.

Menora Mivtachim Holdings reported no remaining Protalix BioTherapeutics position as of Q2 2016 after selling out during the quarter.
Menora Mivtachim Holdings sold 515 Protalix BioTherapeutics shares in Q2 2016, an estimated $4K.
Menora Mivtachim Holdings first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 12 quarters.
Menora Mivtachim Holdings's Protalix BioTherapeutics position peaked at $5.36M in Q2 2013.
28 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2016.

Based on Menora Mivtachim Holdings's 13F filing for Q2 2016, filed 12 Aug 2016.